



RESEARCH TOPIC MEM 12

Testing the selectivity and therapeutic potential of biological treatments targeting different TSLP (Thymic stromal lymphopoietin) isoforms Curriculum MEM

Laboratory name

Mucosal Immunology

Pre-clinical Supervisor

Maria Rescigno

maria.rescigno@hunimed.eu

Abstract

TSLP is a cytokine produced mainly at mucosal barriers and involved in several physiological and pathological immune activities. In humans TSLP is present in two isoforms with different expression patterns and opposite functions. The aim of this project is to test the selectivity and potential neutralization of biological treatments targeting the different TSLP isoforms. This study will be based on patient-derived cell assays for type 2 inflammatory diseases with TSLP as a validated target in ongoing clinical trials, and supported by sample accessibility at the Humanitas Research Hospital.

The project will be carried out as part of The MicrobiomeLab, a translational unit established as an academic-industrial joint initiative between the Immunology & Microbiota Unit of Humanitas University and the Corporate R&D of Alfasigma, and devoted to the study of potential therapeutic effects of microbiome-based therapeutics.

Main technical approaches

Cell culture, immunoassays, biochemistry, molecular biology and animal handling

Scientific references

PMID: 26014813

PMID: 28275684

PMID: 24846652

PMID: 24094650

Type of contract

Scholarship of € 21.000 gross per year awarded by Istituto Clinico Humanitas. This sum is subject to IRPEF income tax and exempt from social security contributions.

Borsa di studio pari a € 21.000 annui lordi erogata da Istituto Clinico Humanitas. Importo soggetto a tassazione IRPEF ed esente da contribuzione previdenziale.



Humanitas University
Via Rita Levi Montalcini, 4
20072 Pieve Emanuele (MI) Italy
Tel +39 0282241 - Fax +39 0282242394
info@hunimed.eu
hunimed.eu
CF 97692990159

www.hunimed.eu